Literature DB >> 9869760

Primary aortic valve replacement with allografts over twenty-five years: valve-related and procedure-related determinants of outcome.

O Lund1, V Chandrasekaran, R Grocott-Mason, H Elwidaa, R Mazhar, A Khaghani, A Mitchell, C Ilsley, M H Yacoub.   

Abstract

OBJECTIVES: Allografts offer many advantages over prosthetic valves, but allograft durability varies considerably.
METHODS: From 1969 through 1993, 618 patients aged 15 to 84 years underwent their first aortic valve replacement with an aortic allograft. Concomitant surgery included aortic root tailoring (n = 58), replacement or tailoring of the ascending aorta (n = 56), and coronary artery bypass grafting (n = 87). Allograft implantation was done by means of a "freehand" subcoronary technique (n = 551) or total root replacement (n = 67). The allografts were antibiotic sterilized (n = 479), cryopreserved (n = 12), or viable (unprocessed, harvested from brain-dead multiorgan donors or heart transplant recipients, n = 127). Maximum follow-up was 27.1 years.
RESULTS: Thirty-day mortality was 5.0%, and crude survival was 67% and 35% at 10 and 20 years. Ten- and 20-year rates of freedom from complications were as follows: endocarditis, 93% and 89%; primary tissue failure, 62% and 18%; and redo aortic valve replacement, 81% and 35%. Multivariable Cox analyses identified several valve- and procedure-related determinants: rising allograft donor age and antibiotic-sterilized allograft for mortality; donor more than 10 years older than patient for endocarditis; rising donor age minus patient age, rising implantation time (from harvest to aortic valve replacement), and donor age more than 65 years for tissue failure; and rising donor age minus patient age, young patient age, rising implantation time, and subcoronary implantation preceded by aortic root tailoring for redo aortic valve replacement. Estimated 10- and 20-year rates of freedom from tissue failure for a 70-year-old patient with a viable valve from a 30-year-old donor and no other risk factors were 91% and 64%; the figures were 71% and 20% if the donor age was 65 years. The rates of freedom from tissue failure for a 30-year-old patient with a 30-year-old donor were 82% and 39%; the figures were 49% and 3% with a 65-year-old donor. Beneficial influences of a viable valve were largely covered by short harvest time (no delay for allografts from brain dead organ donors or heart transplant recipients) and short implantation time.
CONCLUSIONS: Primary allograft aortic valve replacement can give acceptable results for up to 25 years. The late results can be improved by the use of a viable allograft, by matching patient and donor age, and by more liberal use of free root replacement with re-implantation of the coronary arteries rather than tailoring the root to accommodate a subcoronary implantation.

Entities:  

Mesh:

Year:  1999        PMID: 9869760     DOI: 10.1016/s0022-5223(99)70471-x

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  12 in total

Review 1.  Choice of heart valve prosthesis.

Authors:  Peter Bloomfield
Journal:  Heart       Date:  2002-06       Impact factor: 5.994

2.  A single center's experience with the Ross procedure in pediatrics.

Authors:  Edward Kirkpatrick; Roger Hurwitz; John Brown
Journal:  Pediatr Cardiol       Date:  2008-04-10       Impact factor: 1.655

3.  Cryopreserved aortic homograft replacement in 3 patients with noninfectious inflammatory vascular disease.

Authors:  K Sakuma; H Akimoto; H Yokoyama; A Iguchi; K Tabayashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-11

4.  Midterm Follow-up after Cryopreserved Homograft Replacement in the Aortic Position.

Authors:  Samina Park; Ho Young Hwang; Kyung-Hwan Kim; Ki-Bong Kim; Hyuk Ahn
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-02-07

5.  Increased numbers of circulating donor-specific T helper lymphocytes after human heart valve transplantation.

Authors:  M J Welters; F B Oei; L M Vaessen; A P Stegmann; A J Bogers; W Weimar
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

6.  Predictors of early mortality in patients with active infective native or prosthetic aortic root endocarditis undergoing homograft aortic root replacement.

Authors:  Michele Musci; Yuguo Weng; Michael Hübler; Tito Chavez; Naser Qedra; Susanne Kosky; Julia Stein; Henryk Siniawski; Roland Hetzer
Journal:  Clin Res Cardiol       Date:  2009-04-07       Impact factor: 5.460

7.  Decellularized Cryopreserved Allografts as Off-the-Shelf Allogeneic Alternative for Heart Valve Replacement: In Vitro Assessment Before Clinical Translation.

Authors:  Laura Iop; Adolfo Paolin; Paola Aguiari; Diletta Trojan; Elisa Cogliati; Gino Gerosa
Journal:  J Cardiovasc Transl Res       Date:  2017-03-09       Impact factor: 4.132

8.  Homografts in aortic position: does blood group incompatibility have an impact on patient outcomes?

Authors:  Ferdinand Vogt; Bernhard Michael Böll; Anne-Laure Boulesteix; Eckehard Kilian; Giuseppe Santarpino; Bruno Reichart; Christoph Schmitz
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-06

9.  Pregnancy in women with prosthetic heart valves.

Authors:  P G Pieper; A Balci; A P Van Dijk
Journal:  Neth Heart J       Date:  2008-12       Impact factor: 2.380

10.  Aortic insufficiency in a patient with Marfan syndrome after aortic root reconstruction with a tailored-sinus graft.

Authors:  Igor E Konstantinov; Kenton J Zehr
Journal:  Tex Heart Inst J       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.